Neflamapimod for Aphasia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called neflamapimod for individuals with nonfluent variant primary progressive aphasia (nfvPPA), a condition affecting speech and language. The goal is to determine if neflamapimod is safe and effective in improving symptoms like effortful speech or difficulty with sentence structure. Participants will receive either the experimental drug or a placebo, a harmless pill without active medication. This trial may suit those diagnosed with nfvPPA who experience speech difficulties such as halting speech or trouble understanding complex sentences. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important early findings.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Is there any evidence suggesting that neflamapimod is likely to be safe for humans?
Research shows that neflamapimod is generally safe for people. One study found serious side effects to be rare. The most common side effect was falls, affecting about 6 out of every 100 people taking the drug. Other side effects occurred even less frequently.
Neflamapimod has undergone previous testing in people, aiding researchers in understanding its safety. While side effects can occur, studies have ensured the treatment's safety. For those considering joining a trial, these findings suggest that neflamapimod is relatively safe based on past research.12345Why do researchers think this study treatment might be promising for aphasia?
Neflamapimod is unique because it targets a specific enzyme in the brain that plays a role in inflammation, potentially reducing brain inflammation associated with aphasia. Unlike most current treatments for aphasia, which primarily focus on speech therapy and rehabilitation techniques, Neflamapimod offers a pharmacological approach that directly interacts with brain chemistry. Researchers are excited about this treatment because it could provide a new way to improve language recovery by addressing the underlying biological processes, not just the symptoms.
What evidence suggests that neflamapimod might be an effective treatment for aphasia?
Research has shown that neflamapimod might help with certain brain conditions. In one study, patients with dementia who took neflamapimod showed significant improvement in their Clinical Dementia Rating compared to those who took a placebo. This suggests it might support brain function. Although it did not improve memory in patients with mild Alzheimer's, it affected other important brain markers. These results offer hope that neflamapimod, which participants in this trial may receive, could also help treat nonfluent variant primary progressive aphasia (nfvPPA), a condition affecting speech and language.13467
Are You a Good Fit for This Trial?
This trial is for individuals with nonfluent variant primary progressive aphasia (nfvPPA), a condition affecting speech and language. Participants should have a diagnosis of nfvPPA to be eligible. Specific inclusion and exclusion criteria details are not provided, but typically these would outline necessary health conditions and factors that could prevent someone from safely participating.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive neflamapimod or placebo and are monitored for safety, pharmacokinetics, and clinical effects
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Neflamapimod
Find a Clinic Near You
Who Is Running the Clinical Trial?
EIP Pharma Inc
Lead Sponsor
CervoMed, Inc
Collaborator